Who
Michael Patrick Miller
Director
Company insider
Files Form 4 as: Director, Puma Biotechnology; Director, Rigel Pharmaceuticals; Director, BioXcel Therapeutics; EVP, US Commercial, Jazz Pharmaceuticals; Chief Commercial Officer, Vivus.
In numbers
- Trades disclosed
- 114
- Buys
- 0
- Sells
- 49
- Bought
- $0
- Sold
- $4.2M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 30 Apr 2010
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 9 Jan 2026filed 12 Jan 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 9 Jan 2026filed 12 Jan 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 11 Nov 2025filed 13 Nov 2025 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $97K20,000 at $4.86 | filing |
| 11 Jun 2025filed 13 Jun 2025 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 12 Aug 2024filed 13 Aug 2024 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $82K23,358 at $3.49 | filing |
| 18 Jun 2024filed 21 Jun 2024 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 10 Jun 2024filed 11 Jun 2024 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 7 Nov 2023filed 9 Nov 2023 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $71K25,000 at $2.83 | filing |
| 26 Jun 2023filed 28 Jun 2023 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $47K13,500 at $3.45 | filing |
| 13 Jun 2023filed 15 Jun 2023 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 9 Aug 2022filed 10 Aug 2022 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $89K25,000 at $3.55 | filing |
| 1 Jul 2022filed 5 Jul 2022 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.